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Background: Rapidly determining the complex genetic basis of Hypertrophic cardiomyopathy (HCM) is vital to
better understanding and optimally managing this common polygenetic cardiovascular disease.
Methods: A rapid custom Ion-amplicon-resequencing assay, covering 30 commonly affected genes of HCM, was
developed and validated in 120 unrelated patients with HCM to facilitate genetic diagnosis of this disease. With this
HCM-specific panel and only 20 ng of input genomic DNA, physicians can, for the first time, go from blood samples
to variants within a single day.
Results: On average, this approach gained 595628 mapped reads per sample, 95.51% reads on target (64.06 kb),
490-fold base coverage depth and 93.24% uniformity of base coverage in CDS regions of the 30 HCM genes. After
validation, we detected underlying pathogenic variants in 87% (104 of 120) samples. Tested seven randomly
selected HCM genes in eight samples by Sanger sequencing, the sensitivity and false-positive-rate of this HCM panel
was 100% and 5%, respectively.
Conclusions: This Ion amplicon HCM resequencing assay provides a currently most rapid, comprehensive,
cost-effective and reliable measure for genetic diagnosis of HCM in routinely obtained samples.
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Hypertrophic cardiomyopathy (HCM) is regarded as a
most common inherited cardiac disorder (1/500) and
the leading cause of sudden cardiac death in adolescents
0020 [1-4]. So far, over 1000 mutations in at least 30
genes have been reported to responsible for HCM, which
implied an highly genetic heterogeneity and hence result-
ing various clinical phenotypes, ranging from asymptom-
atic forms to sudden cardiac death in the young [3,5-12].
Although disease-causing mutations in MYH7, MYBPC3
and TNNT2 had been considered to explain about half of
HCM patients [8,9], the frequency of each causal variant
is relatively low and most rare mutations are unique in
specific families [13]. Moreover, about 10% HCM patients* Correspondence: david37212@hotmail.com; dwwang@tjh.tjmu.edu.cn
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unless otherwise stated.harbored more than one mutation and thus suffering from
an earlier onset or worse prognosis [2,7]. Therefore, sys-
temic genetic diagnosis for HCM patients was necessary
and recommended by current clinical guidelines [14-17].
For instance, the identification of sudden-death-high-risk
patients could benefit from an implantable cardioverter-
defibrillator in primary prevention [18].
However, conventional Sanger sequencing was too labo-
rious and expensive to content regular clinical practice
[19]. Advancing high throughput next-generation sequen-
cing (NGS) technologies have the potential to solve the
problem by rapidly dissecting large regions at low cost
[1,20-22]. Nevertheless, the current NGS platforms have
several weaknesses, including sample scalability, sequen-
cing time and cost of entry, which need to be addressed
if these technologies are going to service clinical rou-
tine genetic diagnosis [23]. With lowest-price, shortest
running time, minimum start DNA amount and flexible
sequencing-chip reagents, the recent flourishing semicon-
ductor sequencing technique is notable [21,24].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rapid, comprehensive, cost-efficient and reliable assay
for genetic diagnosis of hypertrophic cardiomyopathy
in everyday clinical practice. Implementation of this me-
thod will change diagnosis and understanding of the mo-
lecular etiologies of HCM.
Materials and methods
HCM resequencing panel design
For the HCM resequencing panel targeted genes selec-
tion, recent ten years’ literatures, including prior genetic
detection technique articles, reviews and case-reports of
HCM, were carefully accessed. To recruit a maximum
coverage of the mutation spectrum of this polygeneticTable 1 Selected hypertrophic cardiomyopathy genes
Nr. Gene Ensembl number Chromosome CDS, n
1 MYBPC3 ENSG00000134571 chr11 32
2 MYH7 ENSG00000092054 chr14 38
3 TNNT2 ENSG00000118194 chr1 21
4 ACTC1 ENSG00000159251 chr15 6
5 TNNI3 ENSG00000129991 chr19 7
6 TPM1 ENSG00000140416 chr15 16
7 MYL2 ENSG00000111245 chr12 7
8 MYL3 ENSG00000160808 chr3 6
9 TCAP ENSG00000173991 chr17 2
10 PRKAG2 ENSG00000106617 chr7 18
11 TNNC1 ENSG00000114854 chr3 6
12 CSRP3 ENSG00000129170 chr11 5
13 MYH6 ENSG00000197616 chr14 37
14 PLN ENSG00000198523 chr6 1
15 MYOZ2 ENSG00000172399 chr4 5
16 ACTN2 ENSG00000077522 chr1 21
17 JPH2 ENSG00000149596 chr20 6
18 LAMP2 ENSG00000005893 chrX 11
19 CAV3 ENSG00000182533 chr3 2
20 VCL ENSG00000035403 chr10 22
21 ANKRD1 ENSG00000148677 chr10 9
22 GLA ENSG00000102393 chrX 7
23 LDB3 ENSG00000122367 chr10 16
24 CALR3 ENSG00000269058 chr19 9
25 MYLK2 ENSG00000101306 chr20 12
26 RYR2 ENSG00000198626 chr1 105
27 CASQ2 ENSG00000118729 chr1 11
28 FXN ENSG00000165060 chr9 8
29 LMO4 ENSG00000143013 chr1 4
30 NEXN ENSG00000162614 chr1 12
Ensembl: June 2013 (GRCh37/hg19). CDS, coding sequence; *indicates in silico cove
multiplex PCR.disorder, we designed a currently most comprehensive
HCM-specific resequencing panel including 30 causal
genes that most frequently affected in patients with HCM
(Table 1). Then, primers of overlapping amplicons co-
vering the CDS-region and flanking sequences of each tar-
geted gene were automated designed by Ion AmpliSeq™
Ready-to-Use custom designer platform following guide
of the website (https://www.ampliseq.com/protected/
dashboard.action) (Primers for Semiconductor sequen-
cing are presented in Additional file 1: Table S1). With the
ability to perform ultrahigh-multiplex PCR reaction in
one tube parallelly, the primers were mixed and pro-
vided (Life Technologies, Carlsbad, California, USA) in
two primer-pools. Eventually, 97.96% of the targetedAmplicons, n Target, bp Missed#, bp Coverage*,%
46 3826 9 99.8
54 5808 127 97.8
17 1286 0 100
10 1134 0 100
8 632 0 100
19 1429 0 100
7 501 0 100
8 588 71 87.9
4 504 0 100
22 1795 74 95.9
7 486 10 97.9
6 585 0 100
55 5820 216 96.3
10 1503 364 75.8
10 795 0 100
27 2685 0 100
17 2102 155 92.6
19 1516 0 100
4 456 0 100
37 3405 39 98.9
10 960 0 100
13 1290 0 100
26 2508 0 100
13 1155 22 98.1
22 1791 0 100
165 14904 74 99.5
14 1200 0 100
10 874 32 96.3
6 498 0 100
25 2028 111 94.5
rage of target sequences by multiplex PCR; #indicates in silico missed bases by
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length amplicons.
Patients and DNA sample preparation
With approval from the local ethics committee, 120 un-
related Chinese Han HCM patients confirmed by echo-
cardiography during 2008 to 2013 with written informed
consent were included in this study. Two of the 120
patients were from independent HCM pedigrees, car-
rying known pathogenic mutations rs121913641 and
rs121913637 in the same loci (p.R719Q, p.R719W) in
gene MYH7, respectively. Genomic DNA (gDNA) of each
patient was extracted and RNase managed from peripheral
leukocytes, using a DB-S kit (FUJIFILM Corporation,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. The purified gDNA was then checked with elec-
trophoresis to avoid fragmental degradation and RNA
pollution.
Library preparation and sequencing
Ion Torrent adapter-ligated libraries were builded using
Ion Ampliseq™ Library Kit 2.0 (Life Technologies) fol-
lowing the manufacturer’s protocol within about 5 hours.
Briefly, 20 ng gDNA for every sample was quantitated by
Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA)
for multiplex PCR amplification with each of the two
primer-pools, respectively. The resulting amplicons of the
two primer-pools were mixed together, and then ligated toFigure 1 Semiconductor sequencing flow diagram. Amplicons of 30 HC
primer pools. The about 200 bp amplicons are end-polished, barcodes and
is conducted by Ion One Touch to generate ISPs for semiconductor sequenbarcodes and Ion Torrent adapters (Life Technologies).
Subsequently libraries were purified with AMPure XP
beads (Beckman Coulter, Brea, CA, USA) using 5-cycles
of PCR amplification and further purification, followed by
quantification by Qubit 2.0 fluorometer. In order to in-
crease efficiency and reduce costs, sixteen uniquely bar-
coded libraries were combined together with equal molar
ratios for one 318 chip. Subsequent emulsion PCR and en-
richment of the sequencing beads of the pooled libraries
was performed using the OneTouch system (Life Tech-
nologies) according to the manufacturer’s protocol within
about 5 hours. Finally, 500 Flows (125 cycles) sequencing
was done on the 318- chip using Ion PGM 200 Sequen-
cing Kit (Life Technologies) on the Ion Torrent Personal
Genome Machine (PGM) (Life Technologies) (Figure 1).
Bioinformatic analysis
Raw data from 4.5 hours’ PGM runs were initially pro-
cessed using the Ion Torrent platform-specific software
Torrent Suite v3.6.2 to generate sequence reads, trim
adapter sequences, align to the hg19 human reference ge-
nome, analyze coverage and call variants (Variants Caller
parameter settings see Additional file 1: Table S2). Then,
all variants were annotated with an online-software Var-
iant Effect Predictor (http://asia.ensembl.org/info/docs/
variation/vep/index.html). To predict possible impact of
detected non-synonymous variants in exons, all missense
substitutions were scored and in-silico-function-predictedM genes are amplified by using 20 ng input genomic DNA and two
adapters ligated, purified to become prepared libraries. Emulsion PCR
cing. ISP indicates Ion Sphere Particles.
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html) and PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/). The putative novel pathogenic variants were
further confirmed that were reported neither in the
1000-Genome project database nor in the NCBI dbSNP
database. To calculate the importance of novel muta-
tions, conservation test was performed in patients and
thirteen other species around the mutated position by
COBALT algorithm (http://www.ncbi.nlm.nih.gov/tools/
cobalt/cobalt.cgi).
Criteria for functional mutations
To determine a functional variant, the variant should
be a Sanger sequencing validated coding variant. If the
variant is a previously reported variant, it should be causal
mutations in NCBI ClinVar database or HGMD database.
If the variant is a novel variant, it should in accordance
with none of the following database: the 1000-Genome
project database, the NCBI dbSNP database, UCSC com-
mon SNP database and the 5000 Exmoes database inFigure 2 Sequencing coverage overview of the 30 HCM genes for 120
30 HCM genes for 120 samples. The dashed line indicates the mean coveraExome Sequencing Project (ESP). If the variant is a
missense substitution, it should be evolutionarily con-
served and predicted functional damaged by either SIFT
or Polyphen-2.Sanger sequencing validation
All potential functional variants were validated with
Sanger sequencing in an Applied Biosystems 3130 capil-
lary sequencer using individual primers in both direc-
tions to obsolete false positive errors. The technically
uncovered 1304 bp regions of the 13 targeted genes
were carefully sequenced directly by Sanger sequencing.
No more functional variant was detected in all 120 pa-
tients. To evaluate the sensitivity and false-positive-rate
of this panel, we randomly selected seven genes (MYH7,
MYBPC3, ACTC1, PRKAG2, MYOZ2, ACTN2, JPH2)
and sequenced all exons and flanking regulation regions
directly by Sanger sequencing in eight subjects from the
120 HCM patients.samples. Blue graphs represent the distribution of coverage of the
ge (490X) over the enriched 30 HCM genes (color blocks).
Table 2 Sequencing summary
Measure Value
No. of genes 30
No. of exons 462
No. of amplicons 690






Splice region variant 19
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Study population
One-hundred-and-twenty unrelated patients with HCM
were studied. The mean age of male (85/120) was 45 ±
16 years (1, 78) and the maximal wall thickness was
18.34 ± 5.1 mm (14, 46). For female (35/120) the mean
age was 51 ± 17 years (15, 86) and the maximal wall
thickness was 19.73 ± 4.8 mm (13, 41). The mean left
ventricular ejection fractions of male and female are 58 ±
14 and 62 ± 13, respectively. In the 120 HCM patients,
24.2% (29/120) are hypertrophic obstructive cardiomyop-
athy and 19.2% (23/120) have positive family history. (The
detailed characteristics of HCM Patients were shown in
Additional file 1: Table S3).3′ UTR variant 5




Stop gain variant 6
Frameshift variant 3
No. of known dbSNPs 293
No. of novel variants 140
SNVs, single-nucleotide variants.Sequencing output and coverage
The sequencing of selected regions of 30 HCM-associated
genes on the Ion torrent PGM achieved an average output
of 595628 mapped reads and 95.51% on target per sample
in the 120 HCM specimens. In summary, 99.55% of all
target amplicons was covered at least once, 96.98% am-
plicons was covered at least 20 times, 91.95% amplicons
was covered at least 100 times. The mean uniformity of
base coverage is 93.24% in this panel. The average read
depth in the 64.06 K target region across the 120 samples
was ~490 folds (Figure 2). Moreover, chip-loading-rate
was improved shortly and polyclonal-rate was reduced sig-
nificantly after few trails in the beginning of experiments,
which result in an increase in mean coverage.Mutation detection and sanger sequencing validation
The Ion Torrent platform-specific software Torrent Suite
v3.6.2 and online software Variant Effect Predictor were
employed to align the reads sequences to the human refer-
ence genome build hg19, call variants and bioinformatical
annotate. Criteria for variant identification were a read
coverage of higher than 30-fold. All together, in the 120
patients, 458 known or novel variants were detected by
Semiconductor sequencing and on average 80 variants per
sample. After Sanger sequencing validation, except 25 var-
iants, 433 variants were determined truly exist. Most of
the 25 false-positive miscalls are insertions or deletions
and detected in more than one sample. Of these 433
variants, 345 (80%) are predicted to be noncoding or syn-
onymous, whereas 88 (20%) are non-synonymous, in-
cluding missense mutation and small insertion/deletion,
resulting in the change of amino acids (Table 2). Notably,
we identified at least one functional variant in 104/120
(87%) HCM patients and found more than one functional
variants in 12/120 (10%) HCM patients.Furthermore, the
two known positive pathogenic mutations (rs121913641
and rs121913637) in the two probands were successfully
identified.Sensitivity and false-positive-rate evaluation
To further assess the sensitivity and specificity of this
HCM panel, direct Sanger sequencing of seven randomly
selected genes was performed in eight selected subjects.
Finally, 38 variants were detected by semiconductor se-
quencing, including 35 known variants and 3 novel vari-
ants (Table 3). Compared with Sanger sequencing results,
2 variants were failed to be validated. Therefore, the sensi-
tivity of this HCM panel was evaluated as 100% and the
false-positive-rate was evaluated as 5%.
Discussion
This study provides the first comprehensive HCM-specific
semiconductor sequencing assay, attempting to facili-
tate the clinical diagnosis and optimally manage HCM
patients. Compared with other NGS platform, semi-
conductor sequencing has the highest throughput and
shortest run time [20,21]. From DNA extraction to data
analysis, within only one day, 64.06 kb targeted CDS
and flanking regulating regions of 30 genes in up to six-
teen samples can be parallelly scanned using one Ion
torrent 318-chip. As described in this article, our work-
flow leads to a mean coverage of 490X, allowing the reli-
able detection of sequence variants with high accuracy.
On the whole, we identified 140 novel sequence vari-
ants, which are not listed in the NCBI dbSNP or 1000-
Gemome project databases. By bioinformatical prediction
of SIFT and Polyphen-2, we revealed potential functional
Table 3 Variants detected by semiconductor sequencing of the seven selected genes in eight samples
Gene Position Type Zygosity Nucleotidesubstitution
Variant
frequency P-value




ACTC1 15:35084215 SNP Het C/G 47.94 6.3E-06 413 intron rs3729755 5 Yes
ACTN2
1:236899042 SNP Het G/A 44.09 2.5E-05 254 intron rs2288600 2 Yes
1:236902865 SNP Het A/C 55.93 1.0E-10 59 intron rs2288602 8 Yes
1:236910983 SNP Het G/A 50.83 5.0E-05 303 missense rs80257412 1 Yes
1:236902594 SNP Het C/G 49.1 6.3E-05 387 splice region rs2288601 8 Yes
1:236882303 SNP Hom T/C 100 2.5E-07 299 synonymous rs1341864 8 Yes
1:236883421 SNP Hom C/T 100 2.5E-07 301 synonymous rs1341863 8 Yes
1:236898942 SNP Het G/C 44.86 5.0E-05 185 synonymous rs2288599 1 Yes
1:236925844 SNP Het G/A 47.51 1.6E-05 402 synonymous rs12063382 1 Yes
JPH2
20:42745062 SNP Het C/G 51.85 1.6E-05 542 intron rs184801349 1 Yes
20:42814931 SNP Hom T/C 100 2.0E-04 68 intron rs6031442 2 Yes
20:42747247 SNP Het C/T 51.85 6.3E-06 675 missense rs3810510 6 Yes
20:42743454 SNP Het A/G 61.57 5.0E-05 216 synonymous rs6093935 2 Yes
20:42815190 SNP Het G/A 48.17 4.0E-05 764 synonymous rs1883790 8 Yes
MYBPC3
11:47361084 SNP Hom T/C 99.59 1.3E-06 245 intron rs2856653 8 Yes
11:47364248 SNP Het C/T 48.39 6.3E-06 839 missense CM981325 1 Yes
11:47370041 SNP Het T/C 48.2 4.0E-05 639 missense rs3729989 1 Yes
11:47354782 SNP Het C/T 62.19 2.0E-05 283 stop gained Novel 2 Yes
11:47354787 SNP Het C/T 50.92 6.3E-05 218 synonymous rs1052373 8 Yes
MYH7
14:23882144 SNP Hom T/C 95.41 4.0E-07 283 intron rs2284651 2 Yes
14:23883195 SNP Het G/A 52.63 3.2E-05 779 intron rs3729499 1 Yes
14:23900093 SNP Hom C/T 99.66 1.6E-08 594 intron rs45580436 1 Yes
14:23902974 SNP Het C/A 55.58 2.0E-05 403 intron rs3729992 1 Yes
14:23895179 SNP Het C/T 47.07 5.0E-06 871 missense rs121913641 1 Yes
14:23895180 SNP Het G/A 48.93 7.9E-06 750 missense rs121913637 1 Yes
14:23902806 SNP Het A/G 45.93 2.0E-05 405 missense Novel 8 No
14:23892888 SNP Hom A/G 100 1.6E-08 582 synonymous rs7157716 2 Yes
14:23899060 SNP Het G/A 52.54 5.0E-05 788 synonymous rs735712 1 Yes
14:23900794 SNP Het G/A 45.06 5.0E-05 466 synonymous rs2069542 1 Yes
14:23902753 SNP Het G/A 34.09 6.3E-06 44 synonymous rs2069540 4 Yes
MYOZ2
4:120079159 SNP Hom A/G 98.14 2.0E-07 322 intron rs11721566 8 Yes
4:120106982 SNP Hom T/C 99.54 1.6E-06 217 intron rs7661020 7 Yes
4:120057709 SNP Het A/C 46.36 7.9E-05 302 missense rs76757102 2 Yes
PRKAG2
7:151265714 SNP Hom C/T 100 2.0E-06 177 intron rs2241053 5 Yes
7:151292395 INS Hom –/T 84.34 1.0E-10 281 intron Novel 8 No
7:151292395 SNP Het A/T 30.58 3.2E-05 121 intron rs35348247 6 Yes
7:151478406 SNP Het C/T 51.55 1.6E-05 419 missense rs79474211 1 Yes
7:151483612 SNP Het C/T 47.25 4.0E-05 946 missense rs144857453 1 Yes
#P-value was generated automatically by the Ion Torrent platform-specific software Torrent Suite v3.6.2, detail refer to Supplementary materials.
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patients with HCM. This detection rate is in the expected
range and provides much better performance compared
with previous studies [7,19,25].To evaluate the capability of our Ion amplicon HCM-
specific panel, we carried out assessments of experiments
in several aspects. By Sanger sequencing, we dissected the
panel technically uncovered 1304 bp regions of the 13
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tential functional variants. Besides, the panel presented
satisfactory results with high sensitivity (100%) and low
false-positive-rate (5%) in the following validating tests.
Thus, it is reasonable to believe that our panel has enough
power to detect potential functional variants in HCM
patients.
Ion torrent PGM is considered to have weakness in pro-
ducing long-homopolymer-associated insertion/deletion
errors [21]. Hence, by carefully dissecting the sequences
after validation, we found that this kind of primary error
type was the most miscall reason in this HCM-panel.
Besides, a heterozygous-substitution-miscall (c.T136C,
p.F46L) in gene MYH7 was detected in 58 of 120 subjects
after Sanger sequencing filtration. Since this miscall exists
in high proportion of participants and with high coverage,
we suspected that it is due to mistake during multiplex
PCR. Although this HCM-panel could generate above
false positive mistakes, the following Sanger sequencing
verification can easily eliminate them.
Although there were some other HCM-relevant genes
reported sporadically, such as TTN, MYPN, CRYAB,
MTTL1, RAF1 and FHL1, the connection between them
and HCM pathogenesis were not ascertained [26]. Our
panel was designed for clinical genetic diagnosis, hence,
selected only causal genes. But we will pay attention to
these and other candidate genes constantly, and update
our panels once they are ascertained to be pathogenesis
in the future.
Conclusions
This study established a currently most comprehensive
and reliable semiconductor HCM-specific resequencing
assay and provided a useful, rapid and cost-effective meas-
ure for clinical routine genetic diagnosis of HCM. Im-
plementation of this method will significantly improve
routine diagnosis of HCM and change understanding of
the molecular etiologies of this disease.
Additional file
Additional file 1: Table S1. Primers used for PCR and sequencing,
Table S2. Variant Caller Parameter Settings, Table S3. Patient
Characteristics.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZL carried out the molecular genetic studies, participated in the sequence
alignment and drafted the manuscript. JH collected data and participated in
the statistical analysis. JZ, CC and HW participated in sample collection. HD
helped to design the study, DWW (Dao Wu Wang) and DWW (Dao Wen
Wang) conceived of the study, participated in its design and coordination
and helped to draft the manuscript. All authors read and approved the final
manuscript.Acknowledgements
We thank the patients for consenting to participate in this study and
publication. This work was funded by grants of the National “973” projects
(No. 2012AA02A510; No. 2013CB531105) and National Natural Science
Foundation of China, Project (No. 81170159).
Received: 17 December 2013 Accepted: 11 June 2014
Published: 17 June 2014
References
1. Fokstuen S, Munoz A, Melacini P, Iliceto S, Perrot A, Ozcelik C, Jeanrenaud X,
Rieubland C, Farr M, Faber L, Sigwart U, Mach F, Lerch R, Antonarakis SE,
Blouin JL: Rapid detection of genetic variants in hypertrophic
cardiomyopathy by custom DNA resequencing array in clinical practice.
J Med Genet 2011, 48:572–576.
2. Zou Y, Wang J, Liu X, Wang Y, Chen Y, Sun K, Gao S, Zhang C, Wang Z,
Zhang Y, Feng X, Song Y, Wu Y, Zhang H, Jia L, Wang H, Wang D, Yan C,
Lu M, Zhou X, Song L, Hui R: Multiple gene mutations, not the type of
mutation, are the modifier of left ventricle hypertrophy in patients with
hypertrophic cardiomyopathy. Mol Biol Rep 2013, 40:3969–3976.
3. Maron BJ, Maron MS, Semsarian C: Genetics of hypertrophic
cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol
2012, 60:705–715.
4. Ashrafian H, McKenna WJ, Watkins H: Disease pathways and novel
therapeutic targets in hypertrophic cardiomyopathy. Circ Res 2011,
109:86–96.
5. Bos JM, Ommen SR, Ackerman MJ: Genetics of hypertrophic
cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol 2007,
22:193–199.
6. Ho CY: Hypertrophic cardiomyopathy in 2012. Circulation 2012,
125:1432–1438.
7. Meder B, Haas J, Keller A, Heid C, Just S, Borries A, Boisguerin V,
Scharfenberger-Schmeer M, Stahler P, Beier M, Weichenhan D, Strom TM,
Pfeufer A, Korn B, Katus HA, Rottbauer W: Targeted next-generation
sequencing for the molecular genetic diagnostics of cardiomyopathies.
Circ Cardiovasc Genet 2011, 4:110–122.
8. Watkins H, Ashrafian H, Redwood C: Inherited cardiomyopathies. N Engl J
Med 2011, 364:1643–1656.
9. Liu W, Hu D, Zhu T, Ma Z, Yang J, Xie W, Li C, Li L, Li T, Bian H, Tong Q:
Mutation spectrum in a large cohort of unrelated chinese patients with
hypertrophic cardiomyopathy. Am J Cardiol 2013, 112:585–589.
10. Ho E, Bhindi R, Ashley EA, Figtree GA: Genetic analysis in cardiovascular
disease: a clinical perspective. Cardiol Rev 2011, 19:81–89.
11. Charron P, Komajda M: Molecular genetics in hypertrophic
cardiomyopathy: towards individualized management of the disease.
Expert Rev Mol Diagn 2006, 6:65–78.
12. Seidman JG, Seidman C: The genetic basis for cardiomyopathy: from
mutation identification to mechanistic paradigms. Cell 2001, 104:557–567.
13. Marian AJ: Hypertrophic cardiomyopathy: from genetics to treatment.
Eur J Clin Invest 2010, 40:360–369.
14. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, Helio T, Keren A,
McKenna WJ, Monserrat L, Pankuweit S, Perrot A, Rapezzi C, Ristic A,
Seggewiss H, van Langen I, Tavazzi L: Genetic counselling and testing in
cardiomyopathies: a position statement of the European society of
cardiology working group on myocardial and pericardial diseases.
Eur Heart J 2010, 31:2715–2726.
15. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin
JA: Genetic evaluation of cardiomyopathy–a Heart Failure Society of
America practice guideline. J Card Fail 2009, 15:83–97.
16. Ho CY: Genetic considerations in hypertrophic cardiomyopathy.
Prog Cardiovasc Dis 2012, 54:456–460.
17. Ho CY: Genetics and clinical destiny: improving care in hypertrophic
cardiomyopathy. Circulation 2010, 122:2430–2440. discussion 2440.
18. Giannakopoulos G, Frangos C: [Hypertrophic cardiomyopathy in 2013].
Rev Med Suisse 2013, 9(502):504–507.
19. Waldmuller S, Muller M, Rackebrandt K, Binner P, Poths S, Bonin M,
Scheffold T: Array-based resequencing assay for mutations causing
hypertrophic cardiomyopathy. Clin Chem 2008, 54:682–687.
20. Voelkerding KV, Dames S, Durtschi JD: Next generation sequencing for
clinical diagnostics-principles and application to targeted resequencing
for hypertrophic cardiomyopathy: a paper from the 2009 William
Li et al. Journal of Translational Medicine 2014, 12:173 Page 8 of 8
http://www.translational-medicine.com/content/12/1/173Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn
2010, 12:539–551.
21. Churko JM, Mantalas GL, Snyder MP, Wu JC: Overview of high throughput
sequencing technologies to elucidate molecular pathways in
cardiovascular diseases. Circ Res 2013, 112:1613–1623.
22. Carvill GL, Heavin SB, Yendle SC, McMahon JM, O’Roak BJ, Cook J, Khan A,
Dorschner MO, Weaver M, Calvert S, Malone S, Wallace G, Stanley T, Bye AM,
Bleasel A, Howell KB, Kivity S, Mackay MT, Rodriguez-Casero V, Webster R,
Korczyn A, Afawi Z, Zelnick N, Lerman-Sagie T, Lev D, Moller RS, Gill D,
Andrade DM, Freeman JL: Targeted resequencing in epileptic
encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.
Nat Genet 2013, 45:825–830.
23. Elliott AM, Radecki J, Moghis B, Li X, Kammesheidt A: Rapid detection of
the ACMG/ACOG-recommended 23 CFTR disease-causing mutations
using ion torrent semiconductor sequencing. J Biomol Tech 2012,
23:24–30.
24. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J,
Pallen MJ: Performance comparison of benchtop high-throughput
sequencing platforms. Nat Biotechnol 2012, 30:434–439.
25. Lopes LR, Zekavati A, Syrris P, Hubank M, Giambartolomei C, Dalageorgou C,
Jenkins S, McKenna W, Plagnol V, Elliott PM: Genetic complexity in
hypertrophic cardiomyopathy revealed by high-throughput sequencing.
J Med Genet 2013, 50:228–239.
26. Wilde AA, Behr ER: Genetic testing for inherited cardiac disease. Nat Rev
Cardiol 2013, 10:571–583.
doi:10.1186/1479-5876-12-173
Cite this article as: Li et al.: Rapid molecular genetic diagnosis of
hypertrophic cardiomyopathy by semiconductor sequencing. Journal of
Translational Medicine 2014 12:173.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
